Login
- Dokumenttyp:
- Article; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
- Autor(en):
- Ferreira, João Pedro; Inzucchi, Silvio E; Mattheus, Michaela; Meinicke, Thomas; Steubl, Dominik; Wanner, Christoph; Zinman, Bernard
- Titel:
- Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
- Abstract:
- AIM: To evaluate the effect of empagliflozin on uric acid (UA) levels, antigout medication and gout episodes in the EMPA-REG OUTCOME trial (NCT01131676). MATERIALS AND METHODS: A total of 7020 patients with type 2 diabetes (T2D) were randomized to either empagliflozin (10 or 25 mg) or placebo. The effects of empagliflozin versus placebo on UA concentration were assessed using mixed linear models. A composite outcome of new prescription of antigout medication or gout episode was studied with Cox proportional hazards models. RESULTS: Empagliflozin reduced serum UA levels versus placebo: week 52 adjusted mean treatment difference = -0.37 (95% confidence interval [CI] -0.42, -0.31) mg/dL; this was more pronounced in patients with baseline UA ≥ 7.0 mg/dL versus <7.0 mg/dL: week 52 adjusted mean treatment difference = -0.56 (95% CI -0.68, -0.43) and -0.30 (95% CI -0.37, -0.24) mg/dL, respectively. Among 6607 patients not taking antigout medications at baseline, 5.2% had a gout episode or initiated antigout treatment versus 3.6% in the placebo and empagliflozin groups, respectively: hazard ratio 0.67 (95% CI 0.53, 0.85; P = 0.001). Both components of the composite outcome contributed to the reduction with empagliflozin in the composite. Risk reduction was similar with both empagliflozin doses. CONCLUSIONS: Empagliflozin reduced UA levels and the composite of gout episodes or prescription of antigout medication. These clinically important findings expand the utility of empagliflozin as a potential antigout treatment in patients with T2D, beyond its well-established cardio-renal benefits.
- Zeitschriftentitel:
- Diabetes Obes Metab
- Jahr:
- 2022
- Band / Volume:
- 24
- Heft / Issue:
- 1
- Seitenangaben Beitrag:
- 135-141
- Volltext / DOI:
- doi:10.1111/dom.14559
- PubMed:
- http://view.ncbi.nlm.nih.gov/pubmed/34558768
- Print-ISSN:
- 1462-8902
- TUM Einrichtung:
- Professur für Nephrologie (Prof. Heemann)
BibTeX